GMP-development of cellular therapeutics (JTF Excellent)

In the EXCELLENT project, we aim to give North-East Netherlands a leading position in the cellular therapy field by combining expertise of the UMCG, with that of DEMCON and Scinus Cell Expansion (SCE). Within the project, new production methods and bioreactors are being developed to create two types of cellular therapies for patients: Chimeric Antigen Receptor (CAR) T cell and Tumor Infiltrating Lymphocyte (TIL) therapy. For this approach, UMCG, DEMCON, and SCE collaborate in a translational development project that aims to make academic cell therapy widely available for cancer treatment. The goal is to have a GMP-ready drug product for both types of cellular therapy at the end of this project. In addition, GMP-compliant methods for the key ingredient for CAR-T cells, namely the lentiviral vector, will be developed.

The Just Transition Fund (JTF) contributes to the transition to a climate-neutral Europe. UMCG is a center of expertise for the treatment of hematological and gynecological malignancies.

Co-financed by the European Union.